Coming soon for patients taking XARELTO® (rivaroxaban): Janssen CarePath for XARELTO® and Janssen Select will transition to XARELTO withMe. We are simplifying access to our patient support in one location with a new name and look. Savings card and coverage gap benefits will not change.
What causes a blood clot?
There are a few risk factors, including hospital stays, that can slow down blood flow more than normal, which increases the chance that a blood clot will form.
A clot in a deep vein of the body, usually in the leg is called a deep vein thrombosis (DVT). The clot can block blood flow and lead to painful swelling in the affected limb. People with a DVT may not even know they have it. DVT is a condition that can lead to a pulmonary embolism (PE).
A pulmonary embolism (PE) occurs when a blood clot breaks off and travels through the bloodstream to the lungs. This can cause possibly life-threatening complications. If your child has any symptoms, such as trouble breathing and chest pain, call 911 or get to an emergency room right away.
What is XARELTO®?
XARELTO® is used to treat blood clots or reduce the risk of blood clots from happening again in children from birth to younger than 18 years, after receiving at least 5 days of treatment with injectable or intravenous medicines used to treat blood clots. XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has no known dietary restrictions, no requirements for routine blood tests, and few drug interactions.
XARELTO® is the only DOAC indicated for children from birth up to 18 years to treat and reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE).
XARELTO® has flexible administration options
XARELTO® provides flexible oral administration of a liquid or tablet based on a child’s weight with:
No injections (after at least 5 days of initial blood thinner)
No routine blood test monitoring
Color-coded guidance to help with liquid administration
The dose of XARELTO® depends on your child’s body weight and will be calculated by your child’s doctor. Your child’s doctor will tell you if XARELTO® can be given to your child with or without food. If your child is taking the tablet, do not split the tablet in an attempt to give part of a XARELTO® tablet dose.
If your child is taking the oral suspension, use the syringes provided in the original carton. The suspension will be prepared by the pharmacy. Talk to your child’s doctor about proper administration and any questions you may have about XARELTO®.
Do not switch between the XARELTO® oral suspension or tablet without first talking to your doctor.
XARELTO® may cause an increased risk of bleeding
XARELTO® can cause bleeding, which can be serious, and may lead to death. This is because XARELTO® is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO® your child is likely to bruise more easily, and it may take longer for bleeding to stop. Your child may be at higher risk of bleeding if your child takes XARELTO® and has certain other medical problems.
The risk of bleeding increases if you take XARELTO® with other medicines that also increase your risk of bleeding, such as:
- Aspirin or aspirin-containing products
- Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)
- Warfarin sodium (Coumadin®, Jantoven®)
- Any medicine that contains heparin
- Clopidogrel (Plavix®)
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin norepinephrine reuptake inhibitors (SNRIs)
- Other medicines to prevent or treat blood clots
Always tell your healthcare professional if your child experiences any side effects while taking XARELTO®—keeping an open and honest conversation going with your child’s healthcare professional will help you get your child the best care.